Previous close | 33.64 |
Open | 33.02 |
Bid | 32.96 x 50000 |
Ask | 33.94 x 50000 |
Day's range | 33.02 - 33.02 |
52-week range | 22.35 - 34.48 |
Volume | |
Avg. volume | 190 |
Market cap | 63.316B |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 52.41 |
EPS (TTM) | 0.63 |
Earnings date | 29 Jul 2024 - 02 Aug 2024 |
Forward dividend & yield | 0.36 (1.08%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.